Ambrx Links Its ADC Technology To Japan’s Astellas In Oncology Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
The San Diego biotech has landed another large pharma partner for its antibody-drug conjugation technology as the space continues to attract interest.